Elisa K. Yoo

Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.

S. Lessin, A. Rook, E. K. Yoo, 2001, Journal of the American Academy of Dermatology.

Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma.

D. Grossman, F. Fox, A. Rook, 1998, Current opinion in oncology.